Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial by Asita de Silva, H et al.
Low-Dose Adrenaline, Promethazine, and
Hydrocortisone in the Prevention of Acute Adverse
Reactions to Antivenom following Snakebite: A
Randomised, Double-Blind, Placebo-Controlled Trial
H. Asita de Silva1*, Arunasalam Pathmeswaran1, Channa D. Ranasinha1, Shaluka Jayamanne2,
Senarath B. Samarakoon2, Ariyasena Hittharage3, Ranjith Kalupahana3, G. Asoka Ratnatilaka3,
Wimalasiri Uluwatthage4, Jeffrey K. Aronson5, Jane M. Armitage6, David G. Lalloo7, H. Janaka de Silva1
1Clinical Trials Unit, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka, 2 Polonnaruwa General Hospital, Polonnaruwa, Sri Lanka, 3 Kurunegala Teaching
Hospital, Kurunegala, Sri Lanka, 4Hambantota General Hospital, Hambantota, Sri Lanka, 5Department of Primary Health Care, University of Oxford, Oxford, United
Kingdom, 6Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom, 7 Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Abstract
Background: Envenoming from snakebites is most effectively treated by antivenom. However, the antivenom available in
South Asian countries commonly causes acute allergic reactions, anaphylactic reactions being particularly serious. We
investigated whether adrenaline, promethazine, and hydrocortisone prevent such reactions in secondary referral hospitals
in Sri Lanka by conducting a randomised, double-blind placebo-controlled trial.
Methods and Findings: In total, 1,007 patients were randomized, using a 26262 factorial design, in a double-blind,
placebo-controlled trial of adrenaline (0.25 ml of a 1:1,000 solution subcutaneously), promethazine (25 mg intravenously),
and hydrocortisone (200 mg intravenously), each alone and in all possible combinations. The interventions, or matching
placebo, were given immediately before infusion of antivenom. Patients were monitored for mild, moderate, or severe
adverse reactions for at least 96 h. The prespecified primary end point was the effect of the interventions on the incidence
of severe reactions up to and including 48 h after antivenom administration. In total, 752 (75%) patients had acute reactions
to antivenom: 9% mild, 48% moderate, and 43% severe; 89% of the reactions occurred within 1 h; and 40% of all patients
were given rescue medication (adrenaline, promethazine, and hydrocortisone) during the first hour. Compared with
placebo, adrenaline significantly reduced severe reactions to antivenom by 43% (95% CI 25–67) at 1 h and by 38% (95% CI
26–49) up to and including 48 h after antivenom administration; hydrocortisone and promethazine did not. Adding
hydrocortisone negated the benefit of adrenaline.
Conclusions: Pretreatment with low-dose adrenaline was safe and reduced the risk of acute severe reactions to snake
antivenom. This may be of particular importance in countries where adverse reactions to antivenom are common, although
the need to improve the quality of available antivenom cannot be overemphasized.
Trial registration: http://www.ClinicalTrials.gov NCT00270777
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Introduction
Globally an estimated 421,000 envenomings and 20,000 deaths
occur each year due to snakebite, although the incidence may be
as high as 1,841,000 envenomings and 94,000 deaths [1].
Populations with the highest burden (in rural areas of South Asia,
Southeast Asia, and sub-Saharan Africa) experience high morbid-
ity and mortality because of poor access to often suboptimal health
services; scarcity of antivenom, which is the only specific treatment
for snakebite, may also be a problem [2]. The incidence of
snakebite in Sri Lanka (based on hospital data) is about 200 per
100,000 individuals per year [1,3], one of the highest in the world.
In the North-Central and North-Western Provinces of the country,
which have the highest incidence of bites by highly venomous
snakes, three regional hospitals reported 1,851 snakebite admis-
sions, with 11 deaths due to snakebite during 2000 [4].
Antivenom is the mainstay of treatment for snakebite. Adverse
reactions to the snake antivenoms available in Sri Lanka and other
countries in South Asia, which contains equine proteins, are
common: both acute (anaphylactoid or pyrogenic) and delayed
(serum sickness type) reactions occur [5]. Acute reactions cause the
greatest problem: in most cases, symptoms are mild (urticaria,
nausea, vomiting, headache, and fever), but in up to 40% of cases,
severe systemic anaphylaxis may develop, including bronchospasm
and hypotension [6–9]. In Sri Lanka, only Indian-manufactured
polyvalent antivenoms are available. The rates of adverse reactions
to these antivenoms are high, ranging from 43% to 81% [10–12].
Increasing the safety of treating individuals with snakebite using
antivenom therefore has a high priority.
Prophylactic use of hydrocortisone and antihistamines before
infusion of antivenom is widely practised, although the theoretical
basis for this treatment is unclear and there is limited evidence of
efficacy. Subcutaneous adrenaline (epinephrine) significantly
reduced the incidence of acute adverse reactions in one
prospective study [10], but this study was of inadequate size to
establish the safety of pretreatment with adrenaline [13]. A
retrospective study in Papua New Guinea suggested that
adrenaline pretreatment significantly reduced acute adverse
reaction rates to antivenom but that promethazine or hydrocor-
tisone had no effect [14]. This study has subsequently been
criticised for its poor design [15]. Other studies investigating the
use of pretreatment with hydrocortisone or promethazine have
failed to demonstrate any clear benefit [12,16]. In view of this
uncertainty about the safety and efficacy of pretreatment to reduce
or prevent adverse reactions to antivenom, we conducted a large
randomized, placebo-controlled, double-blind trial to determine
whether low-dose adrenaline, promethazine, and hydrocortisone,
alone and in all possible combinations, are significantly better than
placebo in preventing acute adverse reactions to antivenom in
snakebite victims.
Methods
Subjects and Procedures
The study was developed for secondary referral hospitals in
areas in Sri Lanka with a high incidence of snakebite (Text S1). It
was initiated in March 2005 at Anuradhapura, Kurunegala, and
Polonnaruwa hospitals. Polonnaruwa and Kurunegala hospitals
participated throughout the study to its conclusion in April 2008.
The study was terminated in Anuradhapura in June 2005.
Recruitment was subsequently moved to Embilipitiya hospital
for the period November 2005 to May 2006, and thereafter to
Hambantota hospital until the conclusion of the trial. These
changes were made for a combination of administrative reasons
and poor recruitment rates, and were approved at each step by the
ethics review committee that approved the study. At any given
time, no more than three hospitals participated in the study.
All patients who presented after snakebite were screened for
eligibility by attending clinical staff (Table 1). Those over age 12 y
requiring antivenom were eligible for randomisation. All partic-
ipants provided written informed consent; for those unable to give
consent or less than 16 y of age, a relative provided written
informed consent.
The primary aim was to determine whether low-dose adrenaline
(0.25 ml of a 1:1,000 solution subcutaneously; i.e., 250 micro-
grams), promethazine (25 mg intravenously), or hydrocortisone
(200 mg intravenously), alone or in combination, given as
pretreatment, significantly reduced severe adverse reactions to
antivenom compared with placebo (0.9% NaCl) up to and
including 48 h. All time points relate to time after starting the
antivenom infusion. Adverse reactions to antivenom were
predefined as mild, moderate, and severe based on an interna-
tional classification of anaphylaxis reactions [17] (Table 2). We
also assessed the safety of the pretreatment medication, looking
specifically for complications that might be caused by adrenaline:
arrhythmias, increased systolic blood pressure (BP) (.30 mm Hg
increase), and intracerebral haemorrhage.
Patients were randomized with equal probability to one of eight
different treatments in a 26262 factorial blinded design, using a
triple-dummy technique (Figure 1). Stratified block randomization
was done by hospital site. For each site, computer-generated
random allocation sequences were prepared independently by the
trial statistician. All trial medications were prepared at the Clinical
Trials Unit, Faculty of Medicine, University of Kelaniya, and
packaged in identical sealed envelopes. Syringes containing
adrenaline and adrenaline placebo were clearly marked to ensure
that they were not administered intravenously. The envelopes,
with unique, centre-specific identification numbers, were stored on
site.
Patients were seen by ward doctors within 10 min of admission
and examined. Baseline investigations, such as electrocardiogra-
phy and assessment of blood clotting, were done as indicated.
Randomization occurred after clinical assessment by ward doctors
and after written informed consent had been obtained. Patients
remained under the care of consultant physicians following
management protocols based on current treatment guidelines that
had been approved by the study team. The ward team made all
clinical decisions relating to patient care and administered the
pretreatment medication and antivenom. Monitoring for acute
reactions was carried out independently by groups of three
medically qualified clinical research coordinators dedicated to
each site who were blind to the interventions. Participants were
observed continuously for the first 2 h and then reviewed at 4-h
intervals until 48 h.
Patients were given ten vials of antivenom dissolved in 500 ml of
isotonic saline as an intravenous infusion over 1 h. Antivenom
treatment was repeated as deemed necessary by attending
clinicians, according to clinical judgement. However, patients
were not given further doses of trial medication, even if antivenom
was repeated. Patients were monitored using a clinical observation
protocol developed jointly by consultant physicians and study
coordinators for acute adverse reactions to antivenom and any
adverse reactions to the study drugs. Study-related patient
information was recorded in standardised clinical record forms.
Patients were kept in hospital for at least 96 h after the infusion
of antivenom. If a reaction developed during infusion, or if a
patient developed cardiac arrhythmias, ischaemic changes on the
electrocardiogram, a rise in BP (for systolic, an increase of
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.30 mm Hg, or for diastolic, an increase of .20 mm Hg, from
pretreatment level), a fall in BP (for systolic, a decrease of.20 mm
Hg, or for diastolic, a decrease of.10 mm Hg, from pretreatment
level), or anaphylaxis after the study drug and antivenom,
appropriate treatment (‘‘rescue medication’’) was given solely at
the discretion of the attending clinicians. Reactions to antivenom
were treated by stopping the antivenom infusion temporarily, and
giving, alone or in any combination, 0.25 ml (mild reactions) or
0.5 ml (moderate and severe reactions) of 1:1,000 adrenaline
intramuscularly, 25 mg of promethazine intravenously, or 200 mg
of hydrocortisone intravenously (rescue medication).
Ethics committee approval was received from the Ethics Review
Committee, Faculty of Medicine, University of Kelaniya. An
independent data monitoring committee was provided with
interim analyses when information from groups of 200 new
patients became available. In the light of these analyses and the
results of any other new relevant information, the data monitoring
committee was instructed to advise the principal investigator if, in
the committee’s view, there was proof beyond reasonable doubt
that the data showed that any part of the protocol under
investigation became clearly indicated or contraindicated, either
for all participants or for a specific subgroup of trial participants,
or if it appeared that no clear outcome would be obtained.
However, no data monitoring committee–driven changes to
protocol were made as a result of interim analyses.
Statistical Analysis
Sample size calculations. We estimated that acute adverse
reactions would occur in about 40% of patients who received
antivenom and that a reduction of over 25% in the rate of acute
adverse reactions would correspond to a substantial benefit. Using
the proposed design, a sample size of 1,000 gave 80% power to
detect a 25% relative reduction in adverse reactions from the
current reaction rate by any one treatment, at p,0.01.
Analysis. The prespecified primary outcome measure was the
frequency of severe reactions to antivenom up to and including
48 h after antivenom administration in those allocated to each
treatment compared to those not allocated to that treatment.
Secondary outcomes were rates of severe reactions within 1 or 6 h,
rates of any adverse reactions up to and including 48 h, and acute
adverse reactions to study treatments separately (prespecified as
arrhythmias, intracerebral haemorrhage, or an increase in systolic
BP.30 mm Hg). The 26262 factorial design used for this trial
facilitates primary analyses to determine the main effects of the
three treatments, and allows investigation of two-way and three-
way interactions.
Analyses were undertaken on an intention-to-treat basis using
logistic regression, and took into account clustering by trial site.
The final model included the three trial medications and all three
two-way interaction terms. Odds ratios (ORs) and 95% confidence
intervals for the effects of each treatment and the two-way
interactions were calculated. This superseded our original
intention to compare event rates for those who received a
particular drug versus those not given that drug, and to repeat
these analyses with stratification by other treatments administered
to check for interactions between trial medications. This change
was made on the advice given by the statistical reviewer for the
journal.
No allowance was to be made for multiple comparisons in the
primary analyses but for secondary and, particularly, for tertiary
comparisons, allowance was made for multiple hypothesis testing,
taking into account the nature of the events (including timing,
duration, and severity) and evidence from other studies.
Results
From March 2005 to April 2008, 4,677 patients who presented
after snakebite to trial hospitals were screened, and 1,007 eligible
patients were randomized (53 at Anuradhapura, 16 at Embilipi-
tiya, 152 at Hambantota, 353 at Kurunegala, and 433 at
Polonnaruwa) (Text S2). The main reason for exclusion was lack
of clinical indication for antivenom. Recruitment was stopped
when the target sample size of 1,000 was reached in April 2008.
All the randomized patients completed the study and were
evaluated; there were no protocol deviations.
Table 3 shows the baseline demographic and other clinical
characteristics in the three treatment groups and shows good
balance between the groups. The median time from snakebite to
administration of antivenom was similar at the different hospitals
(median time ranged from 3.9 to 4.6 h). More than 70% of
patients were transferred from smaller rural hospitals. Some of
them had received antivenom (20% of all study patients),
hydrocortisone (25% of all study patients), or promethazine
(9.7% of all study patients) before transfer to a trial hospital. None
of the patients had been given adrenaline. This did not have a
significant effect on the trial outcomes. The biting snake species
was identified in only 25% of the cases.
In total, 752 patients (75%) developed acute reactions to
antivenom within 48 h of administration (Table 4), of which 667
reactions (almost 90%) occurred in the first hour (Figure 2). Of
these, 9% were mild reactions, 48%, moderate, and 43%, severe;
83% of severe reactions occurred in the first hour. After the first
hour the category of reaction changed in 128 patients (12.7%);
this change in reaction category took place before the end of 6 h
Table 1. Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
Patients above 12 y of age Patients who are pregnant or nursing
Patients admitted to hospital
after snakebite in whom
antivenom is indicated
Patients who are currently taking beta- or
alpha-adrenoceptor antagonists, or tricyclic
antidepressants
Patients who give informed
consent
Patients in whom adrenaline may be
contraindicated (this may include patients with
the following): (1) history of ischaemic heart
disease or stroke, (2) uncontrolled
hypertension, (3) tachyarrhythmias
doi:10.1371/journal.pmed.1000435.t001
Table 2. Classification of acute adverse reactions to
antivenom.
Mild Moderate Severe
Facial oedema Abdominal pain Drowsiness or altered consciousness
Pruritus Nausea Systolic BP , 80 mm Hg
Urticaria Vomiting Cyanosis
Fevera Bronchospasm Confusion
Rigora Stridor
aNot in original classification [17] but added to capture all of the systemic
reactions.
doi:10.1371/journal.pmed.1000435.t002
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in 93 of these 128 patients (Figure 2). There was a change in
reaction category after 6 h in only 35 patients, and this included
the one patient whose reaction category changed from moderate
to severe during the second 24 h of observation. Patients were
given rescue medication at the discretion of the attending
clinicians and managed as clinically indicated. In all, 40% of
patients received rescue medication within the first hour: 27% of
all patients with mild or no acute reactions, 47% of all patients
with moderate reactions, and 50% of all patients with severe
reactions.
Adrenaline reduced the rate of severe adverse reactions
compared with placebo at 1 h by 43% (OR 0.57, 95% CI 0.43–
0.75; p,0.001); and by 38% over 48 h (OR 0.62, 0.51–0.74;
p,0.001) (Tables 5 and 6). Neither hydrocortisone nor prometh-
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1000435.g001
Table 3. Patient baseline characteristics by treatment allocation.
Characteristic Adrenaline Hydrocortisone Promethazine Total (n=1,007)
Yes (n=502) No (n=505) Yes (n=510) No (n=497) Yes (n =505) No (n=502)
Male, n (%) 392 (78.1) 384 (76.0) 388 (76.1) 388 (78.1) 383 (75.8) 393 (78.3) 776 (77.1)
Age in years, mean
(standard deviation)
36.0 (13.6) 37.1 (13.5) 36.0 (13.4) 37.1 (13.7) 36.8 (13.8) 36.3 (13.4) 36.5 (13.6)
Time between bite and
antivenom in hours,
median (interquartile
range)
4.3 (2.8–6.8) 4.3 (2.9–6.8) 4.3 (2.8–6.7) 4.3 (3.0–7.2) 4.2 (2.8–7.9) 4.4 (3–6.9) 4.3 (2.9–6.8)
Direct admission, n (%) 136 (27.1) 134 (26.5) 141 (27.7) 129 (26.0) 155 (30.7) 115 (22.9) 270 (26.8)
History of previous
snakebite, n (%)
51 (10.2) 54 (10.7) 54 (10.6) 51 (10.3) 60 (11.8) 45 (9.0) 105 (10.4)
Snake identified (%) 135 (26.9) 124 (24.6) 126 (24.7) 133 (26.7) 124 (24.6) 135 (26.9) 259 (25.7)
Antivenom given before
transfer, n (%)
102 (20.3) 103 (20.4) 96 (18.8) 109 (21.9) 95 (18.8) 110 (21.9) 205 (20.4)
Hydrocortisone given
before transfer, n (%)
127 (25.3) 128 (25.4) 131 (25.7) 124 (25.0) 117 (23.2) 138 (27.5) 255 (25.3)
Promethazine given
before transfer, n (%)
47 (9.4) 51 (10.1) 45 (8.8) 53 (10.7) 46 (9.1) 52 (10.3) 98 (9.7)
History of allergy, n (%) 37 (7.4) 45 (8.9) 39 (7.7) 43 (8.7) 42 (8.3) 40 (8.0) 82 (8.1)
History of bronchial
asthma, n (%)
25 (5.0) 32 (6.3) 32 (6.3) 25 (5.0) 30 (5.9) 27 (5.4) 57 (5.7)
doi:10.1371/journal.pmed.1000435.t003
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azine had any significant effect on the risk of severe adverse
reactions at 1 h or 48 h (Tables 5 and 6). The same pattern was
observed at 6 and 24 h (Tables S1 and S2, respectively). There was
some evidence that the effect of allocation to hydrocortisone in
addition to adrenaline negated the benefit of adrenaline (OR 1.50,
95% CI 1.09–2.07; p = 0.013). Furthermore, adrenaline, but
neither hydrocortisone nor promethazine, reduced the rate of all
reactions, especially at 1 h (Table 4).
Adrenaline and promethazine seemed to be safe (Table 7): only
13 (1.3%) patients died. All deaths were considered by the
supervising physician to be consequences of envenoming or
complications that developed during intensive care treatment for
envenoming (one death from pneumonia, four from sepsis, three
from shock, three from acute renal failure, and two from
respiratory failure). There were significantly more deaths among
those who received hydrocortisone compared to no hydrocortisone
(ten [2%] versus three [0.6%]; OR 3.3, 95%CI 1.28–8.52;
p=0.014) (Table 8). In all, 261 patients had a significant rise in BP
(increase in systolic BP of.30 mm Hg and/or increase in diastolic
BP of .20 mm Hg) within 48 h, but there was no significant
association between rise in BP and trial medications, individually
or combined at 30 or 60 min (Table 7). No patient had an
intracerebral haemorrhage or arrhythmia. There was no signifi-
cant difference in the use of rescue medication between the
treatment groups.
Discussion
Reactions to antivenom present considerable challenges to
clinicians treating snakebite. The frequency of early reactions
varies markedly between individual antivenoms and between
different batches of antivenom from the same manufacturer,
occurring with a frequency that ranges from less than 0.5% up to
87%, although only a small proportion of reactions are life
threatening [7]. The high reaction rates of 75% observed in this
study are in line with the rates of between 43% and 81% that were
observed in three previous Sri Lankan studies [10–12].
Given such high rates of antivenom reactions in some settings, it
is not surprising that pharmacological prophylaxis has been
advocated to reduce acute adverse reactions to antivenom. Before
this study, only the routine use of adrenaline was supported by any
evidence. Low-dose subcutaneous adrenaline given immediately
before antivenom to snakebite victims significantly reduced the
incidence of acute adverse reactions to the antivenom from 43% to
11% [10]. However, the study included only 102 participants,
primarily observed for the first hour after infusion, and could not
Table 4. Outcomes during first hour and 48 h by treatment allocation.
Outcome Reaction Adrenaline Hydrocortisone Promethazine
Total
(n=1,007)
Yes
(n=502) No (n =505)
Yes
(n=510) No (n=497) Yes (n=505) No (n=502)
Reaction during first hour None, n (%) 185 (36.9) 155 (30.7) 170 (33.3) 170 (34.2) 182 (36.0) 158 (31.5) 340 (33.8)
Mild, n (%) 43 (8.6) 41 (8.1) 39 (7.7) 45 (9.1) 29 (5.7) 55 (11.0) 84 (8.3)
Moderate, n (%) 154 (30.7) 161 (31.9) 164 (32.2) 151 (30.4) 167 (33.1) 148 (29.5) 315 (31.3)
Severe, n (%) 120 (23.9) 148 (29.3) 137 (26.9) 131 (26.4) 127 (25.2) 141 (28.1) 268 (26.6)
Any reaction, n (%) 317 (63.1) 350 (69.3) 340 (66.7) 327 (65.8) 323 (64.0) 344 (68.5) 667 (66.2)
ORa (95% CI) for severe
reaction
0.57 (0.43–0.75) 0.86 (0.60–1.24) 0.81 (0.51–1.30)
ORa (95% CI) for any
reaction
0.76 (0.64–0.91) 1.04 (0.85–1.28) 0.81 (0.65–1.02)
Reaction during 48 h None, n (%) 135 (26.9) 120 (23.7) 126 (24.7) 129 (26.0) 128 (25.4) 127 (25.3) 255 (25.3)
Mild, n (%) 29 (5.8) 37 (7.3) 30 (5.9) 36 (7.2) 22 (4.4) 44 (8.8) 66 (6.6)
Moderate, n (%) 184 (36.7) 180 (35.6) 188 (36.9) 176 (35.4) 197 (39.0) 167 (33.3) 364 (36.2)
Severe, n (%) 154 (30.7) 168 (33.3) 166 (32.5) 156 (31.4) 158 (31.3) 164 (32.7) 322 (32.0)
Any reaction, n (%) 367 (73.1) 385 (76.3) 384 (75.3) 368 (74.0) 377 (74.6) 375 (74.7) 752 (74.7)
ORa (95% CI) for severe
reaction
0.62 (0.51–0.74) 0.80 (0.53–1.21) 0.87 (0.50–1.52)
ORa (95% CI) for any
reaction
0.85 (0.71–1.00) 1.07 (0.87–1.32) 1.00 (0.74–1.35)
Rescue medication during
first hour
206 (41.0) 191 (37.8) 186 (36.5) 211 (42.5) 194 (38.4) 203 (40.4)
X2 = 1.09; p= 0.30 X2 = 3.77; p = 0.052 X2 = 0.43; p= 0.51
Time (min) to rescue
medication, mean
(standard error)
30.7 (2.2) 25.9 (1.6) 31.1 (2.1) 25.4 (1.7) 30.7 (2.1) 25.8 (1.7)
t = 1.78; p = 0.08 t = 2.13; p = 0.03 t = 1.86; p= 0.06
All time points relate to time after starting the antivenom infusion.
aFor predictors of severe reaction, ORs were calculated using the main effects and all two-way interactions of the trial medications; for predictors of any reaction, ORs
were calculated using only the main effects of the trial medications because there were no significant interactions.
doi:10.1371/journal.pmed.1000435.t004
Prevention of Reactions to Antivenom
PLoS Medicine | www.plosmedicine.org 5 May 2011 | Volume 8 | Issue 5 | e1000435
Table 5. Risk of severe reaction during the first hour by treatment: main effects and two-way interactions adjusted for clustering
by trial site.
Treatment Severe Reaction
Logistic Regression Model, Main Effects and Two-
Way Interactions
Yes No Total OR 95% CI p-Value
Adrenaline 28 95 123 0.57 0.43–0.75 ,0.001
Hydrocortisone 39 88 127 0.86 0.60–1.24 0.430
Promethazine 37 89 126 0.81 0.51–1.30 0.378
Adrenaline and hydrocortisone 33 93 126 1.50 1.09–2.07 0.013
Adrenaline and promethazine 25 97 122 1.17 0.85–1.61 0.327
Hydrocortisone and promethazine 31 95 126 0.97 0.64–1.47 0.896
Adrenaline, hydrocortisone, and promethazine 34 97 131
Triple placebo 41 85 126
Total 268 739 1,007
There were no three-way interactions. Data are from five hospitals. All time points relate to time after starting the antivenom infusion.
doi:10.1371/journal.pmed.1000435.t005
Figure 2. Progression of type of reaction over 48 h. Numbers within boxes indicate the number of patients according to the highest category
of reaction they had experienced by that time. Numbers above the boxes indicate the number of patients who experienced a higher category of
reaction during the preceding interval. Those who changed from no reaction to a reaction category are indicated by numbers highlighted in yellow.
Those who changed from mild reaction to a higher category are indicated by numbers highlighted in green. Those who changed from moderate to
severe reaction are indicated by numbers highlighted in turquoise. For example the above numbers can be interpreted as follows. At 1 h, there were
315 patients with moderate reaction, and by 6 h, 336 patients were classified as moderate reactions; 33 patients who had had no reaction in 1 h had
a moderate reaction during this interval, six patients who had had mild reaction in 1 h had a moderate reaction during this interval, and 18 patients
who had had moderate reaction in 1 h had a severe reaction during this interval: 336 = (315+33+6)218.
doi:10.1371/journal.pmed.1000435.g002
Prevention of Reactions to Antivenom
PLoS Medicine | www.plosmedicine.org 6 May 2011 | Volume 8 | Issue 5 | e1000435
establish safety, a major concern regarding the use of adrenaline as
a prophylactic agent [13], particularly the risk of intracerebral
haemorrhage [18,19]. Although a recent study from Papua New
Guinea suggested that adrenaline pretreatment was effective [14],
the retrospective design, lack of standardised definitions, and a
selective statistical analysis that did not correct for multiple
comparisons make it difficult to draw firm conclusions from this
study.
Prophylactic use of hydrocortisone and antihistamines before
infusion of antivenom is widely implemented. However, one small
randomized controlled trial demonstrated no benefit from the
routine use of antihistamines [16]. Hydrocortisone takes several
hours to act and may be ineffective as a prophylactic against
acute adverse reactions that develop almost immediately after
antivenom treatment. One small study (52 patients) showed that
intravenous hydrocortisone alone was ineffective in preventing
acute adverse reactions to antivenom, but demonstrated a trend
towards hydrocortisone reducing reactions when given with
intravenous chlorphenamine [12]. However, all of the reactions
were mild or moderate, and the trial was not designed to study
the efficacy of chlorphenamine alone, making it difficult to
interpret the results.
In contrast to these small studies, our trial enrolled just over
1,000 patients, and 752 patients experienced reactions. Our
prespecified primary end point was the development of severe
reactions to antivenom during the first 48 h after its administra-
tion. However, our data clearly showed that more than 80% of
severe reactions occurred during the first hour after antivenom
administration, and only a negligible number of severe reactions
occurred more than 6 h after antivenom administration. Further-
more, about 40% of patients were given rescue medication (i.e.,
adrenaline, hydrocortisone, or promethazine as rescue medication
irrespective of the randomization) in the first hour after antivenom
administration. Such early administration of rescue medication
may have diluted the effects of the randomization on reactions at
the later time points, but should not have affected rates of
reactions at 1 h, and we therefore chose to focus on severe
reactions during the first hour. Previous studies have used a variety
Table 6. Risk of severe reaction up to and including 48 h by treatment: main effects and two-way interactions adjusted for
clustering by trial site.
Treatment Severe Reaction
Logistic Regression Model, Main Effects and Two-
Way Interactions
Yes No Total OR 95% CI p-Value
Adrenaline 33 90 123 0.62 0.51–0.74 ,0.001
Hydrocortisone 41 86 127 0.80 0.53–1.21 0.296
Promethazine 43 83 126 0.87 0.50–1.52 0.629
Adrenaline and hydrocortisone 43 83 126 1.76 1.24–2.50 0.002
Adrenaline and promethazine 33 89 122 1.16 0.80–1.69 0.441
Hydrocortisone and promethazine 37 89 126 1.00 0.65–1.55 0.999
Adrenaline, hydrocortisone, and promethazine 45 86 131
Triple placebo 47 79 126
Total 322 685 1,007
There were no three-way interactions. Data are from five hospitals. All time points relate to time after starting the antivenom infusion.
doi:10.1371/journal.pmed.1000435.t006
Table 7. Heart rate, blood pressure, and number of patients with rise in blood pressure at 30 min and 60 min after pretreatment
administered.
Time after
Pretreatment Measure Adrenaline Hydrocortisone Promethazine
Yes (n=502) No (n=505) Yes (n=505) No (n=502) Yes (n =505) No (n=502)
30 min Heart rate 94.9 (0.91) 94.9 (0.93) 96.2 (0.95) 93.7 (0.89) 95.2 (0.94) 94.6 (0.90)
Systolic BP 114.9 (0.97) 111.5 (1.01) 113.9 (0.98) 112.6 (1.00) 113.5 (1.02) 112.9 (0.95)
Diastolic BP 70.3 (0.68) 68.9 (0.66) 70.3 (0.68) 69.0 (0.65) 69.4 (0.67) 69.9 (0.67)
Number of patients
with rise in BPa
63 (12.6) 52 (10.3) 63 (12.4) 52 (10.4) 66 (13.1) 49 (9.8)
60 min Heart rate 93.4 (0.85) 93.0 (0.88) 94.2 (0.88) 92.3 (0.85) 93.4 (0.85) 93.1 (0.87)
Systolic BP 117.1 (0.85) 114.2 (0.94) 115.6 (0.93) 115.6 (0.87) 116.5 (0.91) 114.7 (0.89)
Diastolic BP 71.5 (0.61) 69.8 (0.64) 71.2 (0.65) 70.2 (0.61) 70.8 (0.63) 70.6 (0.63)
Number of patients
with rise in BPa
84 (16.7) 64 (12.7) 82 (16.1) 66 (13.3) 85 (16.8) 63 (12.6)
All values are mean (standard error).
aAn increase in systolic BP of .30 mm Hg and/or diastolic BP of .20 mm Hg higher than baseline.
doi:10.1371/journal.pmed.1000435.t007
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of different definitions for reactions, and we chose to use an
established international grading [17] in an attempt to standardise
this; rates of severity of reactions are therefore not directly
comparable to previous studies. The factorial design enabled us to
investigate both direct effects and interactions between the
different medications in the most efficient manner.
We found that administration of adrenaline significantly and
substantially reduced the risk of severe adverse reactions in the first
hour and that this was still apparent at 48 h, but neither
hydrocortisone nor promethazine had any clear effect. We have
also unequivocally demonstrated that a dose of subcutaneous
adrenaline of 250 micrograms is safe after snakebite, even where
there is coagulopathy. While pretreatment with hydrocortisone or
promethazine did not reduce severe reaction rates to antivenom
significantly, hydrocortisone negated the beneficial effects of
adrenaline when these treatments were given together. However,
given the multiple comparisons and post-hoc nature of this finding,
it should be interpreted cautiously. Hydrocortisone was also
associated with an increased risk of death, but this finding was
based on very small numbers. Given that hydrocortisone has no
benefit and may even be harmful, we would discourage its current
widespread empirical use as a pretreatment before antivenom
administration.
The mechanism of reactions to antivenom is uncertain. Acute
reactions may be due to type 1 (IgE-mediated) hypersensitivity, but
antivenom reactions often occur in those with no previous
exposure to equine proteins. Although some commercial anti-
venoms have anticomplement activity in vitro, complement
activation has never been clearly demonstrated in patients with
antivenom reactions [6,20,21]. Early reactions are most likely to
be due to a combination of type 1 hypersensitivity, complement
activation, and the effect of aggregates of immunoglobulin or
immunoglobulin fragments, including Fc, which can be found in
even highly refined antivenoms [22]. Although theoretically
cleaving of the IgG molecule into smaller fragments should reduce
the incidence of antivenom reactions, this has not been shown in
clinical studies, and the major influence on reaction rates appears
to be the manufacturing process [7]: there is emerging evidence
that the use of caprylic acid, which results in a more pure IgG
preparation, may reduce reaction rates [23,24]. Slow infusion of
antivenom intravenously (rather than administration by bolus
injection) has also been advocated as a way of reducing reaction
rates, although the only small comparative study of methods of
administration found no difference in the rates and severity of
reactions between a 30-min infusion and intravenous injection
over 10 min. Using a small test dose of antivenom to detect
patients who may develop acute adverse reactions to the
antivenom has no predictive value and can itself cause
anaphylactic reactions [6,25].
The high rate of adverse reactions to antivenom observed in our
study is common to large areas of South Asia, and is an example of
how poor manufacturing and quality control by antivenom
producers causes substantial problems for patients and their doctors.
This highlights the importance of addressing issues of poor quality
and potentially unsafe antivenom. Even well-manufactured anti-
venom may be associated with severe adverse reaction rates of up to
5% [15]. We therefore welcome the recent World Health
Organization guidelines on production, control, and regulation of
antivenom [26]. The need for concerted action by local health and
regulatory authorities, the World Health Organization, and other
stakeholders, including technology transfer programmes between
antivenom manufacturers, to improve the quality of antivenom can
not be overemphasized. Ultimately, the prevention of antivenom
reactions will depend on improving the quality of antivenom. The
increasing recognition of the considerable burden of snakebite and
its treatment will hopefully lead to such improvements. Until these
overdue improvements come about, we have shown that pretreat-
ment with low-dose adrenaline is an effective and safe therapy to
prevent acute reactions to antivenom. This finding may be of
particular relevance in areas where adverse reactions to antivenom
are common. Meanwhile, we continue to reiterate that the need for
careful observation of patients receiving antivenom and prompt
treatment of acute reactions when they occur remains undimin-
ished.
Supporting Information
Table S1 Risk of severe reaction during the first 6 h by
treatment. Main effects and two-way interactions adjusted for
clustering by trial site.
Found at: doi:10.1371/journal.pmed.1000435.s001 (0.04 MB
DOC)
Table S2 Risk of severe reaction during first 24 h by treatment.
Main effects and two-way interactions adjusted for clustering by
trial site.
Found at: doi:10.1371/journal.pmed.1000435.s002 (0.04 MB
DOC)
Table 8. Risk of death by treatment: main effects adjusted for clustering by trial site.
Treatment Death Logistic Regression Model, Main Effects
Yes No Total OR 95% CI p-Value
Adrenaline 0 123 123 0.85 0.39–1.85 0.681
Hydrocortisone 2 125 127 3.30 1.28–8.52 0.014
Promethazine 0 126 126 1.16 0.80–1.68 0.220
Adrenaline and hydrocortisone 3 123 126
Adrenaline and promethazine 2 120 122
Hydrocortisone and promethazine 4 122 126
Adrenaline, hydrocortisone, and promethazine 1 130 131
Triple placebo 1 125 126
Total 13 994 1,007
Data from five hospitals.
doi:10.1371/journal.pmed.1000435.t008
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Text S1 Study protocol.
Found at: doi:10.1371/journal.pmed.1000435.s003 (0.10 MB
DOC)
Text S2 CONSORT checklist.
Found at: doi:10.1371/journal.pmed.1000435.s004 (0.22 MB
DOC)
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Editors’ Summary
Background. Of the 3,000 or so snake species in the world,
about 600 are venomous. Venomous snakes, which are
particularly common in equatorial and tropical regions,
immobilize their prey by injecting modified saliva (venom)
into their prey’s tissues through their fangs—specialized
hollow teeth. Snakes also use their venoms for self-defense
and will bite people who threaten, startle, or provoke them.
A bite from a highly venomous snake such as a pit viper or
cobra can cause widespread bleeding, muscle paralysis,
irreversible kidney damage, and tissue destruction (necrosis)
around the bite site. All these effects of snakebite are
potentially fatal; necrosis can also result in amputation and
permanent disability. It is hard to get accurate estimates of
the number of people affected by snakebite, but there may
be about 2 million envenomings (injections of venom) and
100,000 deaths every year, many of them in rural areas of
South Asia, Southeast Asia, and sub-Saharan Africa.
WhyWas This StudyDone? The best treatment for snakebite
is to give antivenom (a mixture of antibodies that neutralize the
venom) as soon as possible. Unfortunately, in countries where
snakebites are common (for example, Sri Lanka), antivenoms are
often of dubious quality, and acute allergic reactions to them
frequently occur. Although some of these reactions are mild (for
example, rashes), in up to 40% of cases, anaphylaxis—a
potentially fatal, whole-body allergic reaction—develops. The
major symptoms of anaphylaxis—a sudden drop in blood
pressure and breathing difficulties caused by swelling of the
airways—can be treated with adrenaline. Injections of
antihistamines (for example, promethazine) and hydrocortisone
can also help. In an effort to prevent anaphylaxis, these drugs are
also widely given before antivenom, but there is little evidence
that such ‘‘prophylactic’’ treatment is effective or safe. In this
randomized double-blind controlled trial (RCT), the researchers
test whether low-dose adrenaline, promethazine, and/or
hydrocortisone can prevent acute adverse reactions to
antivenom. In an RCT, the effects of various interventions are
compared to a placebo (dummy) in groups of randomly chosen
patients; neither the patients nor the people caring for them
know who is receiving which treatment until the trial is
completed.
What Did the Researchers Do and Find? The researchers
randomized 1,007 patients who had been admitted to
secondary referral hospitals in Sri Lanka after snakebite to
receive low-dose adrenaline, promethazine, hydrocortisone, or
placebo alone and in all possible combinations immediately
before treatment with antivenom. The patients were
monitored for at least 96 hours for adverse reactions to the
antivenom; patients who reacted badly were given adrenaline,
promethazine, and hydrocortisone as ‘‘rescue medication.’’
Three-quarters of the patients had acute reactions—mostly
moderate or severe—to the antivenom. Most of the acute
reactions occurred within an hour of receiving the antivenom,
and nearly half of all the patients were given rescue medication
during the first hour. Compared with placebo, pretreatment
with adrenaline reduced severe reactions to the antivenom by
43% at one hour and by 38% over 48 hours. By contrast,
neither hydrocortisone nor promethazine given alone reduced
the rate of adverse reactions to the antivenom. Moreover,
adding hydrocortisone negated the beneficial effect of
adrenaline.
What Do These Findings Mean? These findings show
that pretreatment with low-dose adrenaline is safe and
reduces the risk of acute severe reactions to snake
antivenom, particularly during the first hour after infusion.
They do not provide support for pretreatment with
promethazine or hydrocortisone, however. Indeed, the
findings suggest that the addition of hydrocortisone could
negate the benefits of adrenaline, although this finding
needs to be treated with caution because of the design of
the trial, as does the observed increased risk of death
associated with pretreatment with hydrocortisone. More
generally, the high rate of acute adverse reactions to
antivenom in this trial highlights the importance of
improving the quality of antivenoms available in Sri Lanka
and other parts of South Asia. The researchers note that the
recent World Health Organization guidelines on production,
control, and regulation of antivenom should help in this
regard but stress that, for now, it is imperative that
physicians carefully monitor patients who have been given
antivenom and provide prompt treatment of acute reactions
when they occur.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000435.
N The MedlinePlus Encyclopedia has pages on snakebite and
on anaphylaxis (in English and Spanish)
N The UK National Health Service Choices website also has
pages on snakebite and on anaphylaxis
N The World Health Organization has information on
snakebite and on snake antivenoms (in several languages);
its Guidelines for the Production, Control and Regulation
of Snake Antivenom Immunoglobulins are also available
N The Global Snakebite Initiative has information on
snakebite
N A PLoS Medicine Research Article by Anuradhani Kasturir-
atne and colleagues provides data on the global burden of
snakebite
N A PLoS Medicine Neglected Diseases Article by Jose´ Marı´a
Gutie´rrez and colleagues discusses the neglected problem
of snakebite envenoming
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